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ABSTRACT 
External beam radiation therapy (XRT) is frequently used to treat refractory disease sites or consolidate remission 
in patients wi th relapsed non-Hodgkin's lymphoma (NHL) prior to autologous bone marrow transplantation 
(ABMT). We report the long-term outcome and toxicities associated with this therapy. We uniformly treated 
552 patients with NHL with total body irradiation, high-dose chemotherapy, and anti-B-cell monoclonal 
antibody-purged ABMT. Of these patients, 152 received XRT to the mediastinum, abdomen, or pelvis (n = 102) or 
other sites (n = 50) prior to ABMT. In this nourandomized series, there was no difference in progression-free sur- 
vival between patients treated with XRT and those not treated with XRT. For patients with indolent histology, there 
was no difference in overall survival between patients treated with XRT and those not treated with XRT. For 
patients with aggressive histology, the median overall survival t ime was 64 months in the XRT patients and 
79 mouths in the patients not treated with XRT (P = .09). The risk of acute transplantation-related d aths was not 
influenced by prior XRT (P = .68). Of patients who received XRT, 12.5% developed secondary myelodysplasia com- 
pared with 5.8% of patients not receiving XRT (P = .01). Patients receiving XRT to the mediastinum or axilla had a 
significantly higher isk of late respiratory death (P = .002). In conclusion, XRT allows refractory patients to become 
eligible for transplantation a d experience a disease-free survival interval equivalent to that of patients who do not 
receive XRT. However, ahigher incidence of non-relapse-associated deaths was observed in patients who received 
XRT. Future work should explore alternative conditioning strategies andaltered timing of XRT, in an attempt to 
limit these late toxicities. 
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INTRODUCTION 
External beam radiation is an important modality in the 
therapy of non-Hodgkin's lymphomas (NHL). Radiother- 
apy is the treatment of choice for early-stage indolent follic- 
ular lymphomas, and it may result in a very prolonged is- 
ease-free interval [1-3]. Sites of bulk disease in patients with 
advanced-stage indolent NHL  and chronic lymphocytic 
leukemia (CLL) respond well to external beam radiation. In 
Current address for Dr. aTedidiah Monson: Valley Regional Cancer Center, 
Modesto, CA. 
newly diagnosed patients with localized aggressive NHL,  
the addition of external beam radiation therapy (XRT) to 
systemic hemotherapy significantly improves both progres- 
sion-free survival (PFS) and overall survival (OS) rates and is 
considered standard care [4-6]. 
The use of high-dose therapy and autologons tem cell 
transplantation (ASCT) has been shown to improve both 
disease-free survival (DES) and OS for chemosensitive 
patients with relapsed aggressive NHL  [7]. Selected patients 
with indolent lymphoma lso may experience extended DFS 
with high-dose therapy and stem cell support compared 
with historical controls [8-12]. 
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Patients with prior bulky sites or residual bulky masses 
after salvage chemotherapy for relapsed NttL  are frequently 
u~eated with XRT prior to ASCT, although the precise role 
and outcome of XRT in this setting have not been well 
defined. Increased transplantation-related morbidity, particu- 
larly interstitial pneumonitis, has been observed in both 
patients with Hodgkin's disease and those with NHL who 
receive XRT immediately prior to ASCT [13]. Fornmately, 
acute treatment-related mortality with autologous transplan- 
tation for NHL is well below 5% in most recent series. With 
longer survival, late complications apart from relapse are 
significant causes of morbidity and mortality Myelodysplastic 
syndrome (MDS) and secondary acute myelogenous leukemia 
(AML) have emerged as major late complications of ASCT, 
particularly in patients with lymphoma, with actuarial risk at 
10 years exceeding 15% in 2 recent reports [14,15]. 
The prognostic impact of XRT followed by ASCT for 
relapsed NHL is largely unknown. This study is a retrospec- 
tive analysis of long-term follow-up from a large cohort of 
patients who received XRT prior to autologous bone marrow 
transplantation (ABMT) for B-cell NHL. These patients 
were uniformly treated with high-dose chemoradiotherapy 
and ABMT with anti-B-cell monoclonal antibody-treated 
marrow. With XRT, patients with bulky residual disease 
enjoyed equivalent DFS after ABMT compared to patients 
who did not require XRT. However, XRT prior to ABMT 
did impart a significant increase in late-occurring toxic 
deaths, due primarily to pneumonitis and MDS. 
PATIENTS AND METHODS 
Selection of Patients 
Between 1982 and 1997, 552 patients had undergone 
ABMT for B-cell NHL at Dana-Farber Cancer Institute. The 
histologies were defined by the International Working For- 
mulation and the Revised European-American Lymphoma 
Classification [16,t7]. Patients were eligible for ABMT if they 
had either elapsed after standard chemotherapeutic regimens 
or had high-risk primary disease in first remission as previ- 
ously described [18-21]. For all patients, a minimal disease sta- 
tus had to be attained through chemotherapy, radiotherapy, or 
both prior to entry, as defined by all lymph node masses <2 cm 
and bone marrow involvement by lymphoma <10% of the 
intertrabecular space [19]. Patients were considered in a mini- 
mal disease state if residual masses >2 cm but <6 cm were 
treated with XRT, even if these localized masses remained 
large after XRT. All protocols were approved by the Dana- 
Farber Cancer Institute Institutional Review Board, and 
informed consent was obtained prior to therapy. 
Previous XRT 
XRT was defined as any dose of localized XRT given 
any time prior to the start of conditioning therapy after 
diagnosis of lymphoma. Subtotal ymphoid radiation as 
therapy for indolent lymphoma was considered, as was lim- 
ited splenic irradiation and craniospinal irradiation. How- 
ever, most patients who were treated with XRT in this series 
were either patients who had residual disease after salvage 
therapy that measured >2 cm, and therefore required XRT 
for transplant eligibility, or patients who initially had stage I 
or II disease and a localized recurrence. For these patients, 
XRT was given immediately prior to ABMT, and the total 
body irradiation (TBI) dose was subtracted from the target 
dose to localized disease sites. Detailed treatment records 
for these patients were obtained, and simulation films, when 
available, were reviewed to evaluate sites of treatment and 
assess potential normal tissue toxicity. 
Conditioning Regimen and Marrow Treatment 
Protocol 
Preparative therapy consisted of cyclophosphamide, 
60 mg/kg body wt, infused on each of 2 consecutive days 
before TBI. Prior to 1994, TBI was administered in frac- 
tionated oses (200 cGy) twice daily on 3 consecutive days 
(total of 1200 cGy) in all but 2 patients. After 1994, all 
patients received 7 fractions (1400 cGy). TBI dose was not 
altered for those patients who received prior XRT. If XRT 
was given immediately before TBI, the XRT dose was 
adjusted by subtracting the TBI dose from the target dose. 
Supportive care was provided as previously described [20]. 
Bone marrow was harvested, treated in vitro with 1 or 
more anti-B-cell monoclonal ntibodies and rabbit comple- 
ment, and cryopreserved, as previously described [20]. Cells 
were rapidly thawed within 24 hours of the completion of 
radiotherapy and diluted in medium containing DNAase 
prior to infusion [20]. 
Follow-up 
All patients had routine physical examinations and labo- 
ratory studies including complete blood count following 
transplantation every 3 months for the first year, then every 
6 months for the second year, then annually. Patients 
underwent bone marrow aspiration and core biopsy for 
unexplained persistently ow peripheral counts, and they 
had appropriate radiographic studies if new symptoms 
evolved. 
Statistical Analysis 
OS rate was measured from date of reinfusion to date of 
death or last known date of remission. PFS, defined as time 
until progression or death in remission, was measured from 
date of reinfusion to date of relapse or date of death in 
remission. Only patients alive and in remission were cen- 
sored at date last known to be in remission. Time-to-event 
end points (PFS, OS) were compared using the log-rank test 
and are plotted using the method of Kaplan and Meier [22]. 
Time to death in remission is adjusted for competing risks. 
Differences in patient characteristics are assessed using the 
Fisher exact est. 
RESULTS 
Patient Characteristics 
Of 552 patients who underwent ABMT for B-cell NHL 
between 1982 and 1997, 322 were male, and the median age 
was 44 years (range, 19-66 years). The histologies of these 
patients included 311 with indolent NHL and 241 with 
aggressive NHL. Ninety-six patients underwent transplan- 
tation in first remission for indolent lymphoma, and 
31 patients underwent transplantation in first remission for 
aggressive lymphoma fter treatment with cyclophos- 
phamide, doxorubicin, vincristine, and prednisone (CHOP) 
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Table I. Characteristics at ABMT for 552 Patients With NHL * 
XRT, n (%) Non-XRT, n (%) 
Total no. of patients 152 400 
Male 84 238 
Female 68 (45) 162 (4 I) 
NHL histology at ABMT 
Follicular center cell grade I or II 59 252 
Diffuse large cell lymphomat 93 (61) 148 (37) 
or mantle cell 
Median age at transplantation (range), y 43 (22-66) 44 (I 9-65) 
T ime of transplantation 
First PR/CR (as part of protocol) 13 I 14 
After relapse 139 (9 I) 286 (72) 
Site of XRT  
Mediastinum 40 -- 
Abdomen 38 - -  
Pelvis 24 - -  
Other 50 --  
*Histologies are as defined by the World Health Organization 
Lymphoma Classification [57]. ABMT indicates autologous bone mar- 
row transplantation; NHL, non-Hodgkin's lymphoma; XRT, external 
beam radiation therapy; PR, partial remission; CR, complete r mission. 
tIncludes 27 patients with an initial diagnosis of indolent follicular 
NIIL or CLL/SLL (chronic lymphocytic leukemia, small lymphocytic 
lymphoma) that ransformed histologically to diffuse large B-cell ym- 
phoma prior to ABMT as previously defined [58]. 
as their only chemotherapy. The remainder of patients had 
relapsed or failed to enter remission with induction chemo- 
therapy. One hundred ninety patients were in complete 
remission at ABMT, whereas 362 were in a minimal disease 
state. This information is summarized in Table 1. 
Externa l  Beam Therapy  
Of these patients, 152 (93 with aggressive NHL and 59 
with indolent NHL) received external beam radiation prior 
to conditioning therapy. Eighty-four were male. Sites 
treated with XRT included mediastinum (n = 40); abdomen, 
including spleen (n = 38); and peMs (n = 24). Fifty patients 
received XRT at other sites, including skin, spine, brain, 
orbit, and extremities. The median age of XRT patients was 
44 years (range, 19-65 years). XRT was completed a median 
of only 1.2 months prior to conditioning therapy; however, 
25% of patients received XRT more than 9 months prior to 
beginning conditioning therapy. 
Treatment  Outcome 
Of the entire population of 552 patients, 328 remain 
alive, and 244 remain free of disease with a median follow- 
up of 75 months. Seven patients (1.3%) died within 
3 months of transplantation, 5 from respiratory failure/diffuse 
alveolar hemorrhage syndrome and 1 each from central ner- 
vous system (CNS) hemorrhage and hepatic veno-occlusive 
disease. Forty-six patients have developed secondary MDS a 
median of 47 months (range, 12-129 months) after ABMT. 
The median survival from diagnosis of MDS in these 
patients was 9.4 months. 
The median DFS from ABMT for the 152 patients who 
received XRT was 60 months compared with 57 months for 
the 400 patients who did not receive XRT (P = .78) (Fig- 
ure 1). In the XRT group, 61 patients relapsed, 16 patients 
in previously involved sites of disease, 9 patients exclusively 
in new sites, and the remainder in old and new sites, usually 
including bone marrow. The median OS for the XRT 
patients was 94 months, compared with 121 months for the 
non-XRT patients (P = .02). For patients with indolent his- 
tology, there was no significant difference in OS, which 
exceeded 120 months in both groups. Among patients with 
aggressive histology, the median OS of patients who 
received XRT was 64 months, compared with 79 months for 
patients who did not receive XRT (P = .09). 
Of the 152 XRT patients, 74 died, of whom 36 died of 
factors not related to NHL. There was only 1 in-hospital 
death not attributed to relapse within 3 months of trans- 
plant, from diffuse alveolar hemorrhage. Causes of death in 
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Figure I. Progression-free survival of patients with indolent histology 
(P = .20) (A) and aggressive histology (P = .86) (B) from autologous bone 
marrow transplantation f r patients who received external beam radia- 
tion therapy (XRT) and patients who did not receive XRT (No XRT). 
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Table 2. Outcome in Patients Treated or Not Treated With XRT Prior to 
ABMT* 
XRT, n (%) Non-XRT, n (%) 
Total no. of patients 152 400 
Alive, in remission 65 179 
Alive, following relapse 12 72 
Deaths 74 (49) 149 (37) 
Causes of death 
Treatment associatedt I 6 
Relapse 38 (25) 106 (26) 
MDS/AML (P = .02) 16 (I I) 23 (5) 
Respiratory deaths:l: 7 (5) 6 (2) 
Cardiac deaths 3 I 
Solid tumors 2 I 
Otherw 7 12 
*XRT indicates external beam radiation therapy; ABMT, autolo- 
gous bone marrow transplantation; MDS, myelodysplastic yndrome; 
AML, acute myelogenous leukemia. 
tDeaths within 3 months of transplantation, P =.68. 
r infectious pneumonia, diffuse alveolar hemorrhage syn- 
drome, and interstitial pneumonitis. 
w causes of death include suicide, radiation enterocolitis, sep- 
sis, perforated viscous, thrombotic thrombocytopenic purpura/ 
hemolytic uremic syndrome, toxoplasmosis, motorcycle accident, endo- 
carditis, and progressive multifocal leukoencephalopathy. 
the remaining 35 patients included 16 patients from MDS, 
7 from respiratory failure including interstitial pneumonitis, 
3 from cardiac auses, 2 from metastatic small cell lung can- 
cer, and 7 from other causes. 
Of the 400 patients who did not receive XRT, 149 patients 
died. There  were 6 in-hospital deaths of non-relapse- 
related causes within 3 months of transplant: 3 from diffuse 
alveolar hemorrhage, and 1 each from respiratory failure, 
CNS hemorrhage, and hepatic veno-occlusive disease. 
Forty-three deaths occurred more than 3 months after 
transplantation a d were not attributed to relapse. Causes 
of death included 23 patients from MDS, 6 patients from 
respiratory failure, 1 from cardiac causes, 1 from solid 
tumor, 2 from perforated viscous, 2 from hemolytic-ure- 
mic syndrome, and 8 from other causes. This information 
is summarized in Table 2. 
A total of 20 patients (13%) in the XRT group developed 
secondary MDS compared with 26' patients (6.5%) not 
receiving XRT (P = .02). When evaluated as a competing risk 
of death, MDS was a significantly more frequent cause of 
death in the XRT group (P = .02). Among patients who died 
more than 3 months after transplantation, 8 of 32 deaths 
(25%) in patients who received mediastinal or axillary XRT 
were of respiratory causes, compared with 10 of 189 deaths 
(5%) in patients not receiving XRT to those locations (P = 
.002). The risk of acute transplantation-related d aths was 
not influenced by prior XRT (P = .68), but time to death not 
attributable to relapse was significantly shorter in the XRT 
group (P = .003). This is summarized in Figure 2. 
Prognost i c  Factors  
In an attempt to identify prognostic variables for these 
patients, a number of factors were examined in univariate 
comparison of PFS and OS using the log-rank test. Patient 
age, sex, original histology, and disease status at transplanta- 
tion had no association with PFS or OS. The timing and 
dose of XRT did not influence PFS, OS, MDS risk, or res- 
piratory deaths: patients who received XRT within 6 weeks 
prior to ABMT had a hazard equivalent to that of patients 
who received XRT earlier (P = .62). There was no associa- 
tion between timing of XRT, location of XRT (P = . 19), 
histology of NHL  or chemotherapy rior to ABMT, and 
subsequent development ofMDS. 
Cox proportional hazards multiple regression models 
for OS performed on the group as a whole identified low- 
grade NHL,  development of MDS, and mediastinal or axil- 
lary XRT as risk factors associated with an increased hazard. 
To further clarify these results, models were run separately 
on patients with low-grade and aggressive NHL. Among the 
patients with indolent histology, only development of MDS 
was associated with a significantly increased hazard. Among 
patients with aggressive disease, only mediastinal or axillary 
XRT significantly increased the risk of death. 
DISCUSSION 
Combinations of chemotherapy and XRT are routinely 
used to obtain a minimal disease state prior to transplanta- 
tion in patients who relapse with NHL. Several small sin- 
gle-institution studies with limited follow-up suggest hat 
patients treated with XRT have similar PFS and OS to his- 
torical control patients who did not receive XRT [13,2 3-2 8]. 
This study is the largest and is the only one with long- 
term follow-up, to evaluate the role of XRT prior to ABMT 
for NHL.  There were 2 major indications for XRT in our 
series. The majority of patients who received XRT had resid- 
ual lymph node masses between 2 cm and 6 cm after induction 
or salvage chemotherapy and were eligible for ABMT only if 
they were treated with XRT therapy. Twenty-five percent of 
patients had received XRT more than 9 months prior to 
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Figure 2. Cumulative incidence of late remission deaths not attribut- 
able to relapse (P = .003) in patients who did or did not receive xter- 
nal beam radiation therapy (XRT) prior to autologous bone marrow 
transplantation. 
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ABMT. There was no significant difference in PFS between 
patients receiving XRT and those not receiving XRT, regard- 
less of the interval between XRT and ABMT. Because patients 
receiving XRT in this and other series have poor prognostic 
features, including bulky disease or incomplete response to 
salvage chemotherapy [29], the observed similar rates of PFS 
suggest a therapeutic benefit for XRT in high-risk patients, 
given the inherit selection bias of the XRT group. 
However, in our study, OS was significantly shorter in 
the XRT group of patients, regardless of the interval between 
XRT and ABMT. Deaths occurring within 3 months of trans- 
plantation were not affected by previous exposure to XRT. 
Late toxicities, especially MDS, pulmonary death, cardiac 
death, and lung cancers, were higher in patients receiving 
XRT therapy, particularly for those patients with aggres- 
sive histologies. 
Few previous tudies have specifically examined the tox- 
icities associated with XRT therapy prior to ABMT for 
NHL. Fifty-seven patients with a history of previous radia- 
tion therapy--including 23 patients with NHL and 32 with 
Hodgkin's disease--underwent ABMT with chemotherapy- 
only conditioning in Seattle [27]. High transplantation- 
related mortality (33 %) was observed, particularly from pul- 
monary complications in a group of patients treated with 
high doses'of carmustine (BCNU). Thirty patients with 
relapsed iffuse large cell lymphoma, most with mediastinal 
disease, were treated with XRT prior to ABMT at Memorial 
Sloan Kettering Cancer Center [23]. Transplantation- 
related toxicities-occurred in 2 patients with diffuse alveolar 
hemorrhage, 1 with pneumonitis, and 1 with cardiomyopa- 
thy. Similar pulmonary toxicities after mediastinal XRT 
have been reported by other groups [25]. However, in a 
series from Vancouver, pulmonary toxicity from ABMT was 
not influenced by prior mediastinal XRT [24]. Follow-up 
was too short in all of these studies to evaluate late events. 
The toxicities of XRT prior to ABMT have also been 
evaluated in patients with Hodgkin's disease. At Princess 
Margaret Hospital, thoracic XRT significantly contributed to 
the risk of ABMT-related death, particularly when given 
immediately prior to ABMT [t3]. A multicenter European 
study found that patients receiving prior radiotherapy had a 
higher isk of relapse after ABMT [30]. However, at Stanford, 
over 100 patients treated with XRT before ABMT had PFS 
and OS rates similar to those of historical controls [26]. Fol- 
low-up again was limited in these studies. In a recently pub- 
lished large series from Spain with a median follow-up of 
30 months, the combination of TBI conditioning and XRT 
prior to transplantation resulted in a significantly increased 
risk of secondary malignancies, particularly MDS [31]. 
In our series, acute alveolar hemorrhage syndrome 
occurred more frequently in patients not receiving XRT, but 
late pulmonary deaths were significantly higher in patients 
treated with XRT, and there were 2 cases of small-cell ung 
cancer in the XRT group. Acute and chronic pneumonitis i  
an established cause of morbidity associated with XRT ther- 
apy [32]. Pulmonary toxicity from radiation therapy is 
directly related to mean lung dose, volume of irradiated 
lung, and timing of any associated chemotherapy [33-35]. 
Acute diffuse alveolar hemorrhage syndrome occurring in 
the setting of ABMT has a high mortality rate and, in other 
series, is correlated to history of lung disease and prior ther- 
apy, including XRT [36-39]. These findings emphasize the 
importance of monitoring pulmonary function in patients 
treated with XRT to the mediastinum with serial examina- 
tions and formal pulmonary function testing. 
The development of MDS, or secondary AML, which 
has a very poor prognosis, is a major late complication of 
ABMT, especially in patients with lymphoma [40]. The risk 
of MDS increases with older patient age, lower numbers of 
stem cells infused, prior fludarabine therapy, and a pro- 
longed period between diagnosis and transplantation [14,15, 
41,42]. Pretransplantation XRT, particularly in conjunction 
with etoposide stem cell mobilization, was identified as an 
independent risk factor for secondary MDS in a recent 
series from the City of Hope Cancer Center [43]. 
In the present series, patients treated with XRT prior to 
ABMT had a significantly higher risk of developing MDS 
than those patients not exposed to previous radiation. Low- 
dose TBI for NHL without stem cell support has a significant 
incidence of secondary AML as a late complication [44]. All 
patients in the present study received TBI as a component of 
conditioning therapy, which appears to increase the risk of sub- 
sequent MDS after ABMT compared with chemotherapy- 
only conditioning [31,45,46]. Although it remains unclear 
whether MDS arises from the reinfused marrow exposed to 
chemotherapy rior to ABMT and/or a complication of the 
high-dose chemoradiotherapy leading to damaged stem cells 
that were not ablated, the majority of patients in our series 
had XRT after bone marrow harvest, before conditioning 
therapy. Moreover, because XRT is also an independent fac- 
tor influencing peripheral blood stem cell mobilization, dam- 
age to the stem cell compartment may occur with localized 
XRT [47]. Stem cells surviving the combination of XRT and 
TBI-containing conditioning therapy are at a relatively 
increased risk of subsequent leukemic transformation. 
Alternative strategies need to be considered to minimize 
these long-term toxicities. Chemotherapy-only conditioning 
regimens have similar esponse rates to TBI-containing reg- 
imens and may decrease risk of MDS, particularly for those 
patients treated with XRT [48]. Radiolabeled monoclonal 
antibodies theoretically can deliver higher doses of radiation 
to tumor sites while sparing normal tissues, and may replace 
external beam irradiation or TBI [49-51]. Twenty-nine 
patients with relapsed B-cell lymphoma have been treated at 
the Fred Hutchinson Cancer Research Center with ablative 
doses of iodine-131 anti-CD20 antibody as conditioning 
and purged autologous stem cell rescue [52]. No MDS has 
been reported since therapy, although the median follow-up 
was only 42 months. However, in a subsequent series of 
52 patients treated in Seattle with a combination of chemo- 
therapy and radiolabeled antibody as conditioning, several 
patients had prolonged chromosomal bnormalities, and 
1 patient thus far has developed MDS [53]. 
There have been limited data evaluating XRT following 
ABMT. Mouse models demonstrate decreased pulmonary 
toxicity when XRT is given following, rather than before, 
chemotherapy [35]. Howevel; in 2 series of patients receiv- 
ing XRT after ABMT, cytopenias requiring transfusions and 
delay of XRT were seen in a significant number of patients 
with NHL [54,55]. Relapse risk was significantly lower in 
patients who received XRT after ABMT using a chemo- 
therapy-only conditioning regimen. Similar results were 
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seen in 31 patients treated in Rochester with chemotherapy- 
only conditioning and XRT after ABMT, with a significantly 
lower relapse rate in patients receiv ing XRT and no 
increased late toxicities [56]. Future studies are needed to 
determine whether or not late toxic deaths from MDS or 
pneumonitis are influenced by altered timing of XRT. 
In conclusion, long-term follow-up of a large group of 
patients treated with XRT before ABMT for NHL  demon- 
strates a higher incidence of late toxic deaths compared with 
patients who do not receive XRT. Routine use of  XRT  
before ABMT is probably best avoided; however, in situa- 
tions of bulky localized recurrences or chemoresistant dis- 
ease, XRT is clearly useful in preparation for consolidative 
transplantation and imparts comparable DFS. Future work 
should explore alternative conditioning strategies and altered 
timing of XRT in an attempt to limit the late toxicities. 
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